Abstract
Uncertainty persists regarding systemic effects of anti-vascular endothelial growth factor agents in the treatment of retinopathy of prematurity (ROP). We performed a retrospective study to investigate systemic outcomes in ROP infants treated with intravitreal bevacizumab (IVB).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have